Introduction
The technique of percutaneous transluminal coronary balloon angioplasty (PTCA) was first introduced by Andreas Gruentzig working in Zurich in 1977 1 . It thus constitutes a relatively new form of treatment. During the early years of its application, coronary angioplasty was confined predominantly to patients with single vessel disease with lesions that were proximal, discrete, noncalcified and subtotal-". Increased operator experience together with continuing refinements in angioplasty 'hardware' (guiding and dilation catheters and guidewires) and imaging equipment have led to application of the technique to an ever widening spectrum of'patientss-'. A particularly important extension of angioplasty has been its widespread use in the treatment of patients with multivessel coronary artery disease 2-5 • Indeed, currently, in many experienced centres over 50% of patients presenting for angioplasty have multivessel disease", Figure 1 illustrates application of the technique to a patient with multivessel disease.
In the treatment of patients with single vessel coronary artery disease who are judged to require mechanical revascularization, coronary angioplasty is generally preferred to coronary bypass surgery2.3. However, the role of coronary nngioplasty in patients with multivessel disease is, at present, uncertainv'.
An important consideration is that coronary artery bypass graft surgery has, in a number of well designed, large scale, controlled clinical trials, been shown to improve symptoms and prolong life in selected subsets of patients with multivessel disease 6 -B , whereas angioplasty has not yet been evaluated in this regardv', However, this situation is about to change. A number of large scale, multicentre trials, comparing the relative efficacy of angioplasty and bypass surgery in patients with multivessel disease, have been set up both in Europe and in North America, and are now in progress. Nevertheless, it will be at least several years before some guidelines will begin to emerge from these trials. Whilst awaiting the results of these trials, it is important to analyse carefully what is already known about angioplasty in the treatment of patients with multivessel disease. Particular concerns about the widespread use of angioplasty in these patients include: (1) the acute outcome, (2) the completeness of revascularization that can be achieved, (3) the high restenosis rate, and (4) the long-term outcome.
Acute outcome
In patients with multivessel disease, angioplasty is associated with a high immediate success rate.
Clinical success (successful dilation of all attempted lesions without any major complication) is achieved in over 90% of such patientsv'. However, in comparison to patients with single vessel disease, major complications (death, non-fatal myocardial infarction and need for emergency bypass surgery) are more common. One of the most comprehensive reports regarding the acute complications of angioplasty is that provided by the results of the 1985-1986 National Heart Lung Blood Institute (NHLBD PTCA Registry", This report analysed the acute outcome of 1802 consecutive patients undergoing their first angioplasty at 15 centres. Of these 1802 patients, 963 (53%) had multivessel disease. In the Registry report, in patients with multivessel disease, the mortality rate at angioplasty was 1.7%, the non-fatal myocardial infarction rate 5% and emergency bypass rate 4%. The equivalent rates for patients with single vessel disease were 0.2%, 3.5%, and 1.8% respectively", The mortality rate of 1.7% in patients with multivessel disease is similar to the recorded 1.6% mortality rate of such patients undergoing bypass surgery at the Cleveland Clinic 10 , one of the most experienced and internationally acclaimed surgical centres. It appears, however, that angioplasty is becoming safer. When the NHLBI reported the results of these 1985-1986 PTCA Registry patients they took the opportunity to compare these results with those observed in patients entered into the 1977-1981 Registry. An encouraging feature of this comparison was the observation that the rate of major complications in patients with multivessel disease undergoing angioplasty in 1985-1986 was similar to the rate observed in patients with single vessel disease in the period 1977-1981 6 • Completeness of revascularization that can be achieved In patients with multivessel disease, some operators attempt to dilate all accessible, significant lesions whereas others only approach the lesion deemed most likely to cause myocardial ischaemia (the so-called 'culprit' lesion)!'. Experience with regard to patients with multivessel disease who undergo coronary artery bypass graft surgery suggests that complete revascularization, that is, graft insertion around all moderate and severe stenoses, leads to a superior result. Follow-up studies of patients with surgical revascularization report that complete revascularization is more effective than incomplete revascularization in protecting patients against future coronary events'P. However, although the concept of complete revascularization is intuitively appealing, 0141-0768/91/ 040224-051$02.00/0 © 1991 The Royal Society of Medicine it may be a little too simplistic merely to classify and compare patients according to the achievement of complete or incomplete revascularization. Patients who have incomplete revascularization may have more extensive disease to begin with and it may be difficult to separate the effect of adequacy of revascularization from the influence of baseline characteristics (such as severity and complexity of coronary disease and degree of left ventricular impairment) on follow-up results",
The concept of completeness of revascularization has significant implications for patients with multivessel disease undergoing coronary angioplasty, as it is often not possible to achieve complete revascularization in these patients!". In recently published series concerning angioplasty in patients with multivessel disease'v!", the percentage of patients achieving complete revascularization ranged between 32%14 and 53%15. The primary reasons for incomplete revascularization are the inability to dilate chronic total occlusions and the inability to dilate diffuse coronary lesions or lesions with excessive tortuosity or angulation!". In the experience of the NHLBI PTCA Registry, a totally occluded vessel was found at baseline in 52% of patients who had incomplete revascularization by PTCA but in only 6% of patients who had complete revascularization by dilation. If new technologies such as laser can improve results in patients with chronic total occlusions, there may be a pronounced increase in the frequency with which complete revascularization is achieved.
A number of studies have examined the relative efficacy of complete and incomplete revascularization by angioplasty in patients with multivessel disease. These studies have provided conflicting observations.
Reeder et at. 6 analysed the 1985-1986 NHLBI patients using logistic regression analysis to adjust for baseline differences in left ventricular function. Comparing 127 patients with complete versus 159 incomplete revascularization, they found no differences between the status of the two cohorts at 2-year followup. Likewise, Thomas et at. 19 found no difference in clinical improvement after multivessel angioplasty between patients who received incomplete rather than complete revascularization. Ghalili et at. reported similar findings at one year follow-up". However, Deligonul et al.14 observed, at a mean follow-up period of 27 months, a significantly increased incidence of coronary bypass grafting in patients with incomplete versus complete revascularization. It is possible that the differences between these studies can be explained by the degree of incomplete revascularization'".
It appears reasonable to suggest that, if a coronary stenosis is in a vessel serving either a small territory or an area of infarction without viable muscle, revascularization of this vessel might not influence long-term outcome". The results of a study by Ghalili et at. support this idea'". In this study, patients who had incomplete revascularization were further subdivided into groups. Patients who had incomplete but adequate revascularization (ie those without significant residual lesions serving large or viable myocardial territory) had a better outcome in terms of symptom relief and need for bypass surgery than patients who had incomplete and inadequate revascularization!".
Restenosis
Restenosis remains the major drawback of angioplasty, occurring in approximately 30% of patients who had initially successful angioplasty->. This complication occurs early and is rare after 6-8 months-", The incidence of restenosis is higher in a patient with dilatation of multiple lesions than in one with single-lesion angioplasty-". This observation is of particular importance when considering patients with multivessel disease, as such patients are more likely to have multilesion angioplasty than patients with single vessel disease 2.s. In addition to an increased incidence of restenosis per patient, patients with multivessel disease may have restenosis in more than one dilated segment-:". Deligonul et aU 4 performed follow-up angiography in 222 patients with multivessel disease who had successful initial angioplasty. The restenosis rate per lesion was 28%. The overall patient restenosis rate was 50%; 37% of patients had restenosis of a single lesion and 13% of patients had multiple restenosis. Myler et at. also reported a similarly high restenosis rate 20. They documented restenosis in 92 of 164 (56%) patients undergoing follow-up angiography after multivessel angioplasty. Sixty patients (36.6%) had restenosis of one or more segments and 32 (19.5%) had restenosis of all dilated segments. Until effective methods of reducing the incidence of restenosis become available, these prohibitively high restenosis rates will continue to dampen enthusiasm for multivessel angioplasty.
The formidably high restenosis rates reported in patients who undergo multilesion angioplasty have prompted considerable interest in the strategy of attempting to dilate only the 'culprit' lesion", Support for such a strategy is provided by the observations of Breisblatt et at. 21 • These workers, in their series of patients with multivessel disease undergoing angioplasty, used thallium scintigraphy to identify the 'culprit' lesion in individual patients and elected to dilate only this lesion initially. Following angioplasty, thallium scintigraphy showed no evidence of ischaemia in a second vascular distribution in the majority of these patients'", In addition, it is important to realize that, in patients with multivessel disease, the greater the number of vessels attempted at angioplasty the greater is the risk of major complications-".
Long-term results
The relatively recent introduction of coronary angioplasty and the lag period of several years before this technique began to be widely applied to patients with multivessel disease have resulted in a paucity oflongterm follow-up informationl", However, the results of a number of studies suggest that, in patients with multivessel disease, angioplasty is associated with a favourable long-term outcome. A follow-up study of 605 such patients achieving initial success at angioplasty at Emory University demonstrated a 3-year freedom from cardiac event rate of 83%22. Data from the 1985-1986 NHLBI Registry show that the outcome for patients with multivessel disease is less favourable than for patients with single vessel disease-", One year mortality after PTCA was 4.6% for patients who had multivessel disease and 1.8% for those who had single vessel disease. The equivalent nonfatal myocardial infarction rates were 8.8% and 5.4% respectively.
It is likely that the results of several ongoing multicentre controlled clinical trials on both sides of the Atlantic will provide useful information regarding the long-term outcome of patients with multivessel disease undergoing angioplasty. These trials are also likely to provide some guidelines regarding relative indications and contraindications for angioplasty in patients with multivessel disease as well as, possibly, determining the relative efficacy of angioplasty and bypass surgery in such patients. The major European trial in this respect is the CABRI (Coronary Artery Bypass Revascularization Investigation) trial. In this trial, eligible patients with multivessel disease are randomized to either angioplasty or bypass surgery. All patients have follow-up angiography at one year and, in the interim, exercise testing to detect residual ischaemia. This trial aims to recruit 2000 patients from 25 participating European centres (3 in the UK). The major equivalent trial in the US is the BARI (Bypass!Angioplasty Revascularization Investigation) trial which aims to recruit about 2500 patients who will be followed-up for 5 years. Endpoints include survival, infarction, symptoms and exercise performance. The RITA (Randomised Intervention Treatment of Angina) trial 24 in an exclusively British trial which, unlike the other trials, randomizes patients with single vessel as well as multivessel disease. Patient recruitment began in March 1988 and it is proposed to recruit at least tOOO patients from 14 participating UK centres. Patients are considered for the trial if the participating cardiologist and surgeon agree that equivalent revascularization could be achieved by either treatment method. Patients will be followed for 5 years and major trial endpoints include death, new myocardial infarction and new coronary angioplasty or coronary artery bypass procedures. Other outcome measures include symptom and employment status, quality of life, exercise tolerance and left ventricular function.
Relative roles of angioplasty and bypass surgery
In the treatment of patients with multivessel disease these two forms of mechanical revascularization are complementary rather than direct competitors. Coronary balloon angioplasty when successful is less traumatic, less costly and requires a shorter hospital stay. While these features will make angioplasty an attractive therapeutic modality, enthusiasm for angioplasty should be tempered with caution. Dilatation of certain types of lesions are associated with a low success rate or a considerably increased risk of major complications!'. For example, in a patient who has a large area of myocardial dysfunction as a result of previous myocardial infarction, and who has arteries with high grade lesions, whose acute occlusion at dilatation would result in cumulative damage equal to approximately 40-50% of the total myocardium, surgical revascularization would appear the wiser option11. Conversely, angioplasty is, at times, preferable to bypass surgery in some patients with multivessel disease. A particular example in this respect is in the treatment of patients who have undergone prior bypass surgery and who, after a variable interim, are judged to require further mechanical revascularization. Repeat bypass surgery has at least a 3-fold greater risk of mortality than the initial operation'". In contrast, there is no significant increase in mortal risk in performing angioplasty in patients with prior coronary artery bypass surgery than in those who have never had bypass surgery. However, in patients with prior bypass surgery, coronary Journal of the Royal Society of Medicine Volume 84 April 1991 227 angioplasty has a 12-fold lower mortality and a 2 to 3 times less frequent incidence of myocardial infarction than repeat surgery", Whether or not angioplasty improves survival in patients with multivessel disease is, as yet, unknown. In contrast, there is now compelling evidence that bypass surgery prolongs life in selected subsets of patients with obstructive coronary artery disease. Included in these subsets are patients with three-vessel disease and impaired left ventricular functionl", three-vessel disease with inducible myocardial ischaemia's", three-vessel disease with severe angina", threevessel disease with multiple risk factors? and, possibly, two-vessel disease where one ofthe diseased vessels is the proximal left anterior descending artery", One could argue that, when mechanical coronary revascularization is deemed necessary in such patients, bypass surgery should, in general, be considered more favourably than angioplasty, at least until more comprehensive data regarding PTCA becomes available.
Conclusions
Since the introduction of angioplasty in 1977, improved operator experience and continuing improvement in angioplasty equipment have resulted in this technique becoming safer and more effective, at least in the short term. Now, in 1990, angioplasty is being routinely applied to patients with multivessel disease, many of whom have complex as well as extensive coronary disease. Coronary angioplasty can be used with a high degree of clinical and angiographic success in selected symptomatic patients with multivessel disease. However, the high restenosis rates reported following multivessel angioplasty as well as the not insignificant, although declining, rates of major acute complications are a matter of concern and have undermined the success of the procedure. Angioplasty appears a useful alternative and, at times, preferable treatment to bypass surgery for selected groups of patients who are at high surgical risk, have had previous bypass surgery or have extensive distal coronary disease and are not suitable candidates for bypass surgery. There is apaucity of long-term follow-up data concerning multivessel PTCA. However, it is likely that a number of ongoing controlled clinical trials will provide useful information in this respect as well as providing some guidelines regarding the relative efficacy of angioplasty and bypass surgery. However, it is important to realize that these trials will not provide all of the answers, and that patients with multivessel disease will continue to challenge our clinical judgement.
